You are here:

dexrazoxane (Cardioxane) 419/07

Advice

In the absence of a submission from the holder of the marketing authorisation

dexrazoxane (Cardioxane) is not recommended for use within NHSScotland for the prevention of chronic cumulative cardiotoxicity caused by doxorubicin or epirubicin use in advanced and/or metastatic cancer patients after previous anthracycline containing treatment.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: dexrazoxane (Cardioxane) 419/07
SMC Drug ID: 419/07
Manufacturer: Novartis Pharmaceuticals UK Ltd
Indication: for the prevention of chronic cumulative cardiotoxicity caused by doxorubicin or epirubicin use in advanced and/or metastatic cancer patients after previous anthracycline containing treatment
BNF Category:
Sub Category: 8.1 Cytotoxic drugs
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 12 November 2007

Back